138 related articles for article (PubMed ID: 38369014)
1. Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors.
Belli C; Curigliano G
Ann Oncol; 2024 May; 35(5):478-480. PubMed ID: 38369014
[No Abstract] [Full Text] [Related]
2. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
[TBL] [Abstract][Full Text] [Related]
3. [Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Courtier B; Hadoux J
Bull Cancer; 2021 Nov; 108(11):989-991. PubMed ID: 34598787
[No Abstract] [Full Text] [Related]
4. Efficacy of Selpercatinib in
Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
6. Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Kander EM; Shah MH; Zhou Y; Goyal A; Palmer JD; Owen DH; Shilo K; Patel G; Raval RR; Gonzalez J; Nguyen M; Olek E; Kherani J; Rothenberg SM; Konda B
Clin Lung Cancer; 2021 May; 22(3):e442-e445. PubMed ID: 32660930
[No Abstract] [Full Text] [Related]
7. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
[TBL] [Abstract][Full Text] [Related]
8. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
Saleh K; Khalife N; Felefly T
Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417
[No Abstract] [Full Text] [Related]
9. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
10. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
11. Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.
Werner RA; Sayehli C; Hänscheid H; Higuchi T; Serfling SE; Fassnacht M; Goebeler ME; Buck AK; Kroiss M
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1833-1834. PubMed ID: 36522435
[No Abstract] [Full Text] [Related]
12. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
[TBL] [Abstract][Full Text] [Related]
15. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
Bruce JY; Bible KC; Chintakuntlawar AV
Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
[No Abstract] [Full Text] [Related]
16. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
[TBL] [Abstract][Full Text] [Related]
17. Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With
Watanabe S; Takeda M; Otani T; Yoshida T; Sakai K; Olek E; Rothenberg SM; Kherani J; French PP; Nishio K; Ito A; Nakagawa K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036231
[No Abstract] [Full Text] [Related]
18. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
19. Selective RET Kinase Inhibitors and Lung Cancer.
Mulligan L
N Engl J Med; 2023 Nov; 389(20):1913-1916. PubMed ID: 37966290
[No Abstract] [Full Text] [Related]
20. Novel RET Fusion
Mweempwa A; Xu H; Vissers JHA; Tothill RW; Pattison AD; Fellowes AP; Thomas DM; Richardson G; Hicks RJ; Grimmond SM; Fox SB; Luen SJ; Desai J; Solomon BJ
JCO Precis Oncol; 2021 Nov; 5():1160-1165. PubMed ID: 34994633
[No Abstract] [Full Text] [Related]
[Next] [New Search]
